Immuneering Co. (NASDAQ:IMRX) Insider Buys $10,023.00 in Stock

Immuneering Co. (NASDAQ:IMRX) insider Harold Eugene Brakewood acquired 3,900 shares of the stock in a transaction dated Friday, March 22nd. The shares were bought at an average cost of $2.57 per share, with a total value of $10,023.00. Following the completion of the transaction, the insider now owns 3,900 shares of the company’s stock, valued at approximately $10,023. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Immuneering Price Performance

IMRX stock opened at $2.43 on Thursday. Immuneering Co. has a twelve month low of $1.90 and a twelve month high of $14.29. The business has a 50 day simple moving average of $5.48 and a 200-day simple moving average of $6.36.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings results on Friday, March 1st. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.06). On average, equities analysts anticipate that Immuneering Co. will post -1.89 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on IMRX. Guggenheim reissued a “neutral” rating on shares of Immuneering in a research report on Thursday, March 14th. Chardan Capital lowered their price target on Immuneering from $21.00 to $16.00 and set a “buy” rating for the company in a report on Friday, March 15th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $3.00 price target (down from $16.00) on shares of Immuneering in a report on Friday, March 15th. Oppenheimer reaffirmed an “outperform” rating and issued a $25.00 price target on shares of Immuneering in a report on Tuesday, March 5th. Finally, TD Cowen reaffirmed a “market perform” rating on shares of Immuneering in a report on Friday, March 15th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.50.

Institutional Investors Weigh In On Immuneering

Large investors have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. raised its stake in shares of Immuneering by 11.4% during the third quarter. Adage Capital Partners GP L.L.C. now owns 195,000 shares of the company’s stock worth $1,498,000 after purchasing an additional 20,000 shares during the last quarter. Exchange Traded Concepts LLC raised its position in Immuneering by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 17,416 shares of the company’s stock worth $128,000 after acquiring an additional 4,417 shares in the last quarter. PNC Financial Services Group Inc. purchased a new position in Immuneering in the third quarter worth $154,000. TD Asset Management Inc raised its position in Immuneering by 100.0% in the third quarter. TD Asset Management Inc now owns 284,476 shares of the company’s stock worth $2,185,000 after acquiring an additional 142,238 shares in the last quarter. Finally, HighVista Strategies LLC purchased a new position in Immuneering in the second quarter worth $2,567,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.